Olanzapine in cocaine dependence: A double-blind, placebo-controlled trial

American Journal on Addictions

Volumn 18, Issue 1, 2009, Pages 48-52

  Hamilton, Joseph D ^a,b,c,d   Nguyen, Quang X ^c   Gerber, Robert M ^c   Rubio, Nancy B ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b EDUCATION AND CLINICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Baylor College of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; OLANZAPINE; PLACEBO;

ABDOMINAL PAIN; ADDICTION SEVERITY INDEX SCALE; ADULT; AKATHISIA; AMNESIA; ARTICLE; ASTHENIA; BEHAVIOR CHANGE; BLEPHARITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRAVING QUESTIONNAIRE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG URINE LEVEL; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM SCALE; HUMAN; INCREASED APPETITE; LEG EDEMA; MALE; MUSCLE TWITCH; OPISTHOTONUS; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PATIENT COUNSELING; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SPEECH ARTICULATION; STUTTERING; TACHYCARDIA; THERAPY EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; URINALYSIS; WEIGHT GAIN; XEROSTOMIA;

EID: 60549096315     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490802544318     Document Type: Article

References (20)

1. Soyka M, De Vry J. Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependence. Eur Neuropsychopharmacol. 2000;10:325-332.
2. Brown ES, Nejtek VA, Perantie DC, Thomas NR, Rush AJ. Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23:384-388.
3. Meil WM, Schechter MD. Olanzapine attenuates the reinforcing effects of cocaine. Eur J Pharmacol. 1997;340:17-26.
4. Rasmussen T, Sauerberg P, Nielsen EB, et al. Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naïve mice. Eur J Pharmacol. 2000;402:241-246.
5. Van Campenhout N, De Haes P, Meert TF. Inability of antipsychotics to antagonize the cueing properties of cocaine in rats. Pharmacol Biochem Behav. 1999;64:435-438.
6. Longo LP. Olanzapine for cocaine craving and relapse prevention in two patients. J Clin Psychiatry. 2002;63:595-596.
7. Sattar SP, Bhatia SC. Olanzapine for cocaine cravings and relapse prevention. J Clin Psychiatry. 2003;64:969.
8. Sattar SP, Grant K, Bhatia S, Petty F. Potential use of olanzapine in treatment of substance dependence disorders. J Clin Psychopharmacol. 2003;23:413-415.
9. Bano MD, Mico JA, Agujetas M, Lopez ML, Guillen JL. Eficacia del antipsicotico olanzapine en el tratamiento del abuso de cocaine en pacientes en mantenimiento con metadona: interaccion en los niveles plasmaticos [Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients: interaction with plasma levels]. Actas Esp Psiquiatr. 2001;29:215-220.
10. Tsuang J, Marder SR, Han A, Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002;63:1180-1181.
11. Kampman KM, Pettinati H, Lynch KG, Sparkman T, O'Brien CP. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70:265-273.
12. Weiss RD, Griffin ML, Hufford C, et al. Early prediction of initiation of abstinence from cocaine: Use of a craving questionnaire. Am J Addict. 1997;6:224-231.
13. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976.
15. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
16. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
17. Smelson DA, Roy A, Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry. 1997;42:984.
18. Tsuang JW, Eckman T, Marder S, Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol. 2002;22:629-630.
19. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002;47:671-675.
20. Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: Randomized, double-blind trial. J Clin Psychopharmacol. 2000;20:305-310.